Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 41.30 as of 2026-09-26T00:16:17.710Z.
Consensus retrieved: 2026-09-10T03:58:52.956Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-26T00:16:17.710Z.
Quote observation: 2026-09-25T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 10fdbeb150bcad31bc030c110c9f0c4a3b87f33d2b32019f4e65bb0dcc9467f6
Forward PE Ratio (41.30) = Dated Quote Price ($370.29) / Consensus Forward EPS ($8.97)
FORWARD PE RATIO
41.30
SECTOR MEDIAN · HEALTHCARE
18.73
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+120.50%
vs the sector median at left
West Pharmaceutical Services, Inc.
Market Cap
$26.06B
Forward PE Ratio
41.30
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $26.06B | 41.30 |
| Quest Diagnostics Incorporated (DGX)vs › | $26.08B | 21.12 |
| Labcorp Holdings Inc. (LH)vs › | $25.39B | 16.87 |
| Incyte Corporation (INCY)vs › | $25.11B | 32.93 |
| BioNTech SE (BNTX)vs › | $24.75B | N/A |
| Medline Inc. (MDLN)vs › | $29.34B | 23.25 |
| Zoetis Inc. (ZTS)vs › | $29.79B | 11.36 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $30.10B | 13.53 |
| Centene Corp. (CNC)vs › | $30.53B | 12.87 |
| Mettler-Toledo International Inc. (MTD)vs › | $30.55B | 31.94 |
Trailing P/E
47.4
reported TTM EPS
Forward P/E
41.3
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $8.97 implies +14.7% EPS growth vs the reported trailing $7.82.
At the dated quote price of $370.29, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $8.97 | $8.87 – $9.04 | 10 | 41.3x |
| 2027-12-31 | $9.98 | $9.47 – $10.19 | 10 | 37.1x |
| 2028-12-31 | $11.35 | $10.33 – $12.49 | 5 | 32.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
